The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Tay-Sachs Disease— Carrier Screening, Prenatal Diagnosis, and the Molecular Era: An International Perspective, 1970 to 1993
Abstract
OBJECTIVES: To provide an update of the international experience with carrier screening and prenatal diagnosis for Tay-Sachs disease (TSD), to assess the impact of these efforts, and to review the recent developments in DNA technology with application to TSD carrier detection and screening. DESIGN: Through the International TSD Testing, Quality Control, and Data Collection Center, all testing centers in the world were surveyed annually to assess overall experience with carrier testing and prenatal diagnosis. Quality control and laboratory surveillance of testing centers were performed through an annual assessment, using samples provided by the center. SETTING: Tay-Sachs disease testing centers around the world. PARTICIPANTS: Nearly 1 million young adults from both Jewish and non-Jewish populations. INTERVENTION: Gene product screening (enzyme testing) and DNA-based mutation analysis (in some populations). MAIN OUTCOME MEASURE: Impact of screening program on disease incidence. RESULTS: Data from all centers in the international TSD network on experience with TSD carrier testing and prenatal diagnosis since 1974 indicated that more than 36,000 heterozygotes were identified and 1056 couples found to be at risk for TSD in their offspring. A total of 2416 pregnancies at increased risk for TSD were monitored by amniocentesis or chorionic villus sampling. A dramatic decrease in the incidence of TSD in the Jewish populations was demonstrated. With both serum and leukocyte proficiency testing, there have been only 16 instances (of 845 cumulative laboratory evaluations) of one or more errors reported by a laboratory since 1983 resulting in nonaccreditation. CONCLUSIONS: This analysis represents a prototypic effort in coordinating adult education, carrier testing, and genetic counseling directed toward prospective prevention of a uniformly fatal childhood disease and demonstrates that such an effort can dramatically affect disease incidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434
N-Acetyl-β-glucosaminidases in human spleen
Robinson, D., & Stirling, J. L. (1968) · Biochemical Journal · doi:10.1042/bj1070321 · Cited by 517
Tay-Sachs Disease: Detection of Heterozygotes and Homozygotes by Serum Hexosaminidase Assay
O'Brien, J. S., Okada, S., Chen, A., & Fillerup, D. L. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007022830104 · Cited by 388
Leinekugel, P., Michel, S., Conzelmann, E., & Sandhoff, K. (1992) · Human Genetics · doi:10.1007/bf00219337 · Cited by 327
Conzelmann, E., & Sandhoff, K. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.3979 · Cited by 275
Gaucher disease: gene frequencies in the Ashkenazi Jewish population.
Beutler, E., Nguyen, N. J., Henneberger, M., Smolec, J. M., McPherson, R. A., West, C., & Gelbart, T. (1993) · PubMed · Cited by 230
Tay-Sachs Disease: Prenatal Diagnosis
O’Brien, J. S., Okada, S., Fillerup, D. L., et al. (1971) · Science · doi:10.1126/science.172.3978.61 · Cited by 173
Human beta-hexosaminidase alpha chain: coding sequence and homology with the beta chain.
Myerowitz, R., Piekarz, R., Neufeld, E. F., Shows, T. B., & Suzuki, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7830 · Cited by 163
Some influences on public participation in a genetic screening program
Becker, M. H., Kaback, M. M., Rosenstock, I. M., & Ruth, M. V. (1975) · Journal of Community Health · doi:10.1007/bf01318939 · Cited by 142
Self-citationAdult (Chronic) GM2 Gangliosidosis
Rapin, I. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500020048008 · Cited by 137
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Laboratory standards and guidelines for population-based cystic fibrosis carrier screening
Grody, W. W., Cutting, G. R., Klinger, K. W., Richards, C. S., Watson, M. S., & Desnick, R. J. (2001) · Genetics in Medicine · doi:10.1097/00125817-200103000-00010 · Cited by 456
Gregg, A. R., Aarabi, M., Klugman, S., Leach, N. T., Bashford, M. T., Goldwaser, T., Chen, E., Sparks, T. N., Reddi, H. V., Rajkovic, A., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01203-z · Cited by 367
Biochemical consequences of mutations causing the GM2 gangliosidoses
Mahuran, D. J. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00074-5 · Cited by 296
Ferreira, C. R., & Gahl, W. A. (2017) · Translational Science of Rare Diseases · doi:10.3233/trd-160005 · Cited by 263
Metadata
- Authors
- Kaback, M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1993-11-17
- Volume
- 270
- Issue
- 19
- Pages
- 2307
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2024036407
- Cited by
- 258
- References
- 30
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tay-Sachs Disease— Carrier Screening, Prenatal Diagnosis, and the Molecular Era: An International Perspective, 1970 to 1993. https://app.cochat.ai/papers/10.1001/jama.1993.03510190063028
- The paper
- Kaback, M. (1993). Tay-Sachs Disease— Carrier Screening, Prenatal Diagnosis, and the Molecular Era: An International Perspective, 1970 to 1993. JAMA. https://doi.org/10.1001/jama.1993.03510190063028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.